DARE — Dare Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $26.42m
- $10.72m
- $0.01m
- 14
- 34
- 57
- 27
Annual cashflow statement for Dare Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.4 | -38.7 | -30.9 | -30.2 | -4.05 |
| Depreciation | |||||
| Non-Cash Items | 0.58 | 1.18 | 2.14 | 2.61 | 3.64 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.54 | 8.73 | 10.7 | -11.3 | 5.76 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -25.2 | -28.8 | -18.1 | -38.9 | 5.39 |
| Capital Expenditures | -0.018 | -0.015 | -0.063 | -0.629 | -0.573 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale of Business | |||||
| Cash from Investing Activities | -0.018 | -0.015 | -0.063 | -0.629 | -0.573 |
| Financing Cash Flow Items | — | — | — | 4.72 | -0.002 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 25.1 | 75.8 | 1.34 | 15.6 | 0.434 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.111 | 47 | -17 | -23.9 | 5.19 |